Contracts › 75F40123C00197
75F40123C00197: Seamless Design for Multicomponent Endpoints for Drug Development in Rare Diseases
Awarded to Regents of the University of Michigan by Food and Drug Administration (FDA).
$1.2Mobligated
$1.2Mpotential value
29 September 2026current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75F40123C00197 |
|---|---|
| Awardee | Regents of the University of Michigan |
| Awarding agency | Food and Drug Administration (FDA) |
| Awarding office | FDA OFFICE OF ACQ GRANT SVCS |
| NAICS | 541714 Research and Development in Biotechnology (Except Nanobiotechnology) |
| PSC | B504 Special Studies/Analysis- Chemical/Biological |
| Place of performance | MI |
| Offers received | 1 |
| Period of performance | 22 September 2023 to 29 September 2026 |
| Potential end | 29 September 2026 |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 04 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541714 contracts · All expiring contracts · USASpending record